Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220116

Enrollment

11962

Registered

2022-06-04

Start date

2022-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with CRC aged over 20 years who were diagnosed between May 2014 and January 2021 by using the International Classification of Diseases, 10th revision (ICD-10) codes in the database. -Patients who received FTD/TPI and/or regorafenib.

Exclusion criteria

Exclusion criteria: 1) FTD/TPI- or regorafenib-treated patients with diseases other than CRC; 2) patients who received other chemotherapy except bevacizumab simultaneously with FTD/TPI 3) patients who received other chemotherapy simultaneously with regorafenib.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
time to treatment discontinuation, adverse events, post-treatment	—

Contacts

Public ContactMedical Affairs Division Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Co., Ltd.

th-ftdtpirwd@taiho.co.jp+81-3-3293-5394

Outcome results